Navigation Links
Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
Date:11/5/2010

PALO ALTO, Calif., Nov. 5, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company was awarded three grants totaling $733,437 under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).  The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010.  The grants will be used to advance Neuraltus' product pipeline, including NP001, NP002 and NP003.  

Neuraltus currently is evaluating NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) in an ongoing Phase 1 study. NP001 is a novel small molecule that regulates macrophage activation, with potential application to a number of neurodegenerative diseases, including ALS, Alzheimer's disease, Parkinson's disease and multiple sclerosis.  NP002, Neuraltus' small molecule, nicotinic receptor agonist currently is in a Phase 1/2 study for L-dopa-induced dyskinesias (muscle movement disorders), a primary side effect of L-dopa treatment in Parkinson's disease patients.  In addition, Neuraltus is developing NP003, an orally bioavailable, small molecule designed to treat lysosomal storage disorders such as Fabry's disease and Gaucher's disease, as well as Parkinson's disease.

Andrew Gengos, Neuraltus' President and CEO, commented, "We are very pleased to receive this grant.  There remain significant unmet needs in the treatment of neurodegenerative diseases, specifically, ALS, Alzheimer's disease and Parkinson's disease.  Each of Neuraltus' programs represents a first-in-class approach to treating these indications.  With the help of the QTDP grant, Neuraltus will be able to further develop NP001, NP002 and NP003."

Under the QTDP program, tax credits or grants were made available to companies with 250 or less employees to encourage therapeutic discovery projects that showed a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions; reduce the long-term growth of health care costs in the United States; or significantly advance the goal of curing cancer within 30 years.  For additional information on the QTDP program, please visit http://grants.nih.gov/grants/funding/QTDP_PIM.

About Neuraltus Pharmaceuticals, Inc.

Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases.  Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and multiple sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease.  Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.

Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine; and Ari Azhir, PhD.  In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.  For more information on Neuraltus, please visit www.neuraltus.com.


'/>"/>
SOURCE Neuraltus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/23/2017)... PLEASANTON, Calif. , May 23, 2017 /PRNewswire/ ... world,s most innovative medical devices for pressure ulcer ... at the American Association of Critical Care Nurses, ... Houston May 22-25. The Leaf Patient ... designed specifically for the hospital environment.  The system ...
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation of ... winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... supplier of garden pea seed. As demand grew, the small company located in Moscow, ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance ... communities in northern Virginia and DC, is announcing a cooperative charity event in ... Alzheimer’s and other disorders that lead to memory impairment. , The Insight Memory ...
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom ... technical specifications . , 2017 has seen an explosion of token launches by ... offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article on medGadget ... $6.81 billion by the year 2024 according to a new report. The article also ... made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and ... offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice ...
Breaking Medicine News(10 mins):